Cannara Biotech Inc., a vertically integrated producer of premium-grade cannabis and derivative products with two mega facilities based in Québec spanning over 1,650,000 sq. ft., announced its fiscal fourth quarter and fiscal year 2022 financial and operating results for the three-month and full year periods ended August 31, 2022. The company recorded a record high of $12 million in quarterly revenue (84% YoY increase) and a Net Income of $2.6 million. Full year revenues were $36 million, a 108% increase compared to 2021. The company also delivered its sixth consecutive quarter of positive Adjusted EBITDA of $2.5M, and $5.3M for fiscal year 2022. Cannara Biotech Inc. is a Bristol Investor Relations client.

Read the full press release here: Cannara Biotech Inc. Reports Record Q4 and 2022 Fiscal Year Financial Results